RhumbLine Advisers’s Alaunos Therapeutics TCRT Stock Holding History

RhumbLine Advisers’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-39	Closed	-$273	–	4325
2024 Q2	$273	Sell	39 -3	-7%	-$36	﹤0.01%	4314
2024 Q1	$766	Hold	42	–	–	﹤0.01%	4167
2023 Q4	$451	Hold	42	–	–	﹤0.01%	4203
2023 Q3	$840	Hold	42	–	–	﹤0.01%	4198
2023 Q2	$3.25K	Buy	+42	New	+$3.4K	﹤0.01%	4151
2022 Q2	–	Sell	-1,460	Closed	-$143K	–	3232
2022 Q1	$143K	Sell	1,460 -10	-0.7%	-$1.28K	﹤0.01%	2829
2021 Q4	$240K	Sell	1,470 -29	-2%	-$6.37K	﹤0.01%	2783
2021 Q3	$409K	Buy	1,499 +42	+3%	+$12.8K	﹤0.01%	2632
2021 Q2	$577K	Sell	1,457 -366	-20%	-$171K	﹤0.01%	2502
2021 Q1	$984K	Sell	1,823 -146	-7%	-$90.9K	﹤0.01%	2197
2020 Q4	$744K	Buy	1,969 +195	+11%	+$77.5K	﹤0.01%	2268
2020 Q3	$671K	Sell	1,774 -286	-14%	-$126K	﹤0.01%	2159
2020 Q2	$1.01M	Buy	2,060 +706	+52%	+$315K	﹤0.01%	2039
2020 Q1	$497K	Sell	1,354 -17	-1%	-$8.8K	﹤0.01%	2164
2019 Q4	$971K	Buy	1,371 +22	+2%	+$15.1K	﹤0.01%	2099
2019 Q3	$866K	Sell	1,349 -9	-0.7%	-$7.14K	﹤0.01%	2110
2019 Q2	$1.19M	Buy	1,358 +205	+18%	+$141K	﹤0.01%	1986
2019 Q1	$666K	Sell	1,153 -14	-1%	-$5.85K	﹤0.01%	2197
2018 Q4	$327K	Buy	1,167 +370	+46%	+$146K	﹤0.01%	2499
2018 Q3	$382K	Sell	797 -62	-7%	-$26.6K	﹤0.01%	2388
2018 Q2	$389K	Buy	859 +24	+3%	+$15.2K	﹤0.01%	2420
2018 Q1	$491K	Sell	835 -29	-3%	-$18.1K	﹤0.01%	2216
2017 Q4	$536K	Sell	864 -156	-15%	-$112K	﹤0.01%	2204
2017 Q3	$939K	Buy	1,020 +13	+1%	+$11.5K	﹤0.01%	2008
2017 Q2	$940K	Buy	1,007 +53	+6%	+$52K	﹤0.01%	1979
2017 Q1	$907K	Buy	954 +33	+4%	+$30.7K	﹤0.01%	1982
2016 Q4	$739K	Buy	921 +9	+1%	+$8.11K	﹤0.01%	2013
2016 Q3	$771K	Buy	912 +2	+0.2%	+$1.61K	﹤0.01%	1961
2016 Q2	$749K	Buy	910 +114	+14%	+$124K	﹤0.01%	1963
2016 Q1	$886K	Buy	796 +1	+0.1%	+$1.02K	﹤0.01%	1878
2015 Q4	$991K	Buy	795 +100	+14%	+$165K	﹤0.01%	1803
2015 Q3	$940K	Buy	695 +8	+1%	+$13.2K	﹤0.01%	1801
2015 Q2	$1.24M	Buy	687 +131	+24%	+$203K	﹤0.01%	1728
2015 Q1	$898K	Buy	556 +111	+25%	+$165K	﹤0.01%	1924
2014 Q4	$338K	Buy	445 +14	+3%	+$7.43K	﹤0.01%	2511
2014 Q3	$171K	Hold	431	–	–	﹤0.01%	2810
2014 Q2	$261K	Buy	431 +27	+7%	+$15K	﹤0.01%	2678
2014 Q1	$278K	Sell	404 -16	-4%	-$10.7K	﹤0.01%	2579
2013 Q4	$273K	Buy	420 +1	+0.2%	+$595	﹤0.01%	2644
2013 Q3	$248K	Buy	419 +2	+0.5%	+$901	﹤0.01%	2663
2013 Q2	$131K	Buy	+417	New	+$116K	﹤0.01%	3174

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

RhumbLine Advisers's TCRT Position: Q3 2024 in Review

RhumbLine Advisers sold out of Alaunos Therapeutics (TCRT) in Q3 2024, closing a stake of 39 shares — an estimated $273 sold.

RhumbLine Advisers first reported a position in TCRT in Q2 2013 and held it in 41 quarters. The position peaked at $1.24M in Q2 2015. 29 funds tracked by Wall St. Rank hold TCRT as of Q3 2024.

RhumbLine Advisers reported no remaining Alaunos Therapeutics position as of Q3 2024 after selling out during the quarter.
RhumbLine Advisers sold 39 Alaunos Therapeutics shares in Q3 2024, an estimated $273.
RhumbLine Advisers first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 41 quarters.
RhumbLine Advisers's Alaunos Therapeutics position peaked at $1.24M in Q2 2015.
29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.